# Bioequivalence of Amphotericin B Liposome for Injection

> **NCT05913921** · PHASE1 · COMPLETED · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Amphotericin B liposome for injection
- **DRUG:** AmBisome

## Key facts

- **NCT ID:** NCT05913921
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-02
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913921, "Bioequivalence of Amphotericin B Liposome for Injection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05913921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*